Mechanism of Clonidine Patch in Reducing Agitation

Primary Mechanism of Action

Clonidine acts as a presynaptic alpha-2 adrenergic receptor agonist that suppresses sympathetic nervous system outflow throughout the brain 1
In the prefrontal cortex, postsynaptic alpha-2 agonism enhances noradrenergic neurotransmission, strengthening the regulatory role of the prefrontal cortex responsible for top-down guidance of attention and thought 2

Clonidine decreases excess central sympathetic outflow through medullary alpha-2 receptors and peripherally counters aberrant vasoconstriction 3
The medication alters REM/NREM sleep patterns in a dose-dependent manner, which may contribute to its calming effects 1
Somnolence is a significant effect of the medication, which contributes to its utility in managing agitation 4, 2

Clonidine is used as a less common but effective agent for management of agitated patients, alongside more frequently used medications like antipsychotics and benzodiazepines 4, 5
The transdermal patch formulation offers advantages including weekly applications and placement anywhere on the body (not necessarily over affected areas) 3

For transdermal application, patches delivering 0.1 to 0.3 mg daily are typically used 6
When used for agitation, doses are typically given at night because a significant effect of the medication is somnolence 4

Common side effects include somnolence, fatigue, irritability, insomnia, nightmares, dry mouth, sedation, bradycardia, and syncope 2, 7
Hypotension and bradycardia are potential concerns that require monitoring 8
Side effects typically improve after the first week of treatment and largely resolve by week 4 7

Sudden cessation of clonidine therapy can lead to severe rebound hypertension, tachycardia, and other symptoms of sympathetic overactivity 8, 6
The medication should be tapered gradually if used for more than 9 weeks to decrease risks of rebound effects 6

Clonidine has a higher specificity to alpha-2A receptors compared to similar medications like guanfacine, which may explain differences in adverse effect profiles, such as more pronounced sedative effects 2
While both clonidine and guanfacine share the same mechanism of action, clonidine is approximately ten times more potent than guanfacine 2

The American Academy of Child and Adolescent Psychiatry recommends clonidine as a second-line adjunctive agent for managing aggression in children with ADHD and comorbid conduct disorder when first-line treatments have failed to adequately control aggressive outbursts 9, 10
Clonidine may be added to mood stabilizers like lithium or divalproex sodium when stimulant medication has improved core ADHD symptoms but aggressive outbursts remain problematic in patients with ADHD and persistent aggression 9, 10
The treatment algorithm positions clonidine before atypical antipsychotics, with risperidone reserved for pervasive, severe, persistent aggression that poses acute danger to self or others 9, 10
The American College of Obstetricians and Gynecologists suggests that clonidine could be considered as an adjunct agent in pregnancy following a risk-benefit discussion, with limited published information suggesting no association with adverse pregnancy or developmental outcomes 11

In breastfeeding patients, caution is advised due to limited data, with most cases reporting no adverse infant effects, but clonidine is detectable in human milk and infant serum, and infants should be monitored for drowsiness and hypotonia 11